The device is intended to provide relief from lumbar facet pain, restoring facet joint function while preserving native anatomy. It is a non-fusion and minimally invasive solution.
“The Glyder device fills a gap in the current care continuum between short-term treatments such as injections and irreversible procedures such as lumbar fusion, which requires advanced degeneration and comorbidities such as intervertebral disc disease or radiculopathy,” said Jim Bullock, president and CEO of Zyga Technology.
More articles devices:
Aurora Spine, MedAssets enter into contract
Stryker, Medtronic, Aurora Spine & more — 11 key notes
Zimmer net earnings up 7.9% ahead of Biomet acquisition completion — 10 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
